Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07420751 · ClinicalTrials.gov registry record · NA
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
A NA study of NF2-related Schwannomatosis, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07420751 is a NA study of NF2-related Schwannomatosis that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07420751, a NA study of NF2-related Schwannomatosis, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to investigate the usability of auto-captioning glasses for adults diagnosed with NF2-related schwannomatosis and loss of hearing. The primary objective of the study is to determine the feasibility and acceptability of auto-captioning glasses in this population. Participants will be asked to: * Use the glasses at their discretion for 12 weeks * Report their feedback at 3 and 12 week timepoints via online surveys and remote qualitative interviews
Conditions Studied
Interventions
- DEVICE Auto-captioning Glasses
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02 |
| Est. Completion | 2026-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07420751
The ClinicalTrials.gov registry entry for NCT07420751 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NF2-related Schwannomatosis appearing as the primary indexed condition, and to 1 intervention - of which Auto-captioning Glasses is the first listed.
NCT07420751 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07420751 about?
NCT07420751 is a clinical study titled "Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis". The goal of this clinical trial is to investigate the usability of auto-captioning glasses for adults diagnosed with NF2-related schwannomatosis and loss of hearing. The primary objective of the study is to determine the feasibility and acceptability of auto-captioning glasses in this population. P...
What is the current status of trial NCT07420751?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-02. Estimated completion is 2026-12.
What conditions does trial NCT07420751 study?
This clinical trial studies the following conditions: NF2-related Schwannomatosis.
What interventions are being tested in trial NCT07420751?
The interventions under investigation include: Auto-captioning Glasses (DEVICE).
Who is sponsoring clinical trial NCT07420751?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07420751 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.